VeraDermics

Veradermics offers career opportunities related to advancing dermatology.

Veradermics aims to make dermatology treatments simple, proven, and reliable.

The page provides information for general inquiries and connecting with Veradermics's team.

Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company.

The page describes Veradermics website's privacy policy.

Veradermics’ oral drug **VDPHL01** shows **statistically significant hair growth** in a Phase 3 trial for male pattern hair loss. The extended-release minoxidil formulation met all primary and secondary endpoints in both once-daily and twice-daily dosing arms. Early results indicate **consistent and robust efficacy** in target hair regrowth.

Oct 2026Veradermics, Inc.News article

Veradermics reports positive topline results from its open-label Phase 2 Study ‘207’ evaluating **VDPHL01** for female pattern hair loss, showing rapid hair regrowth onset and sustained growth. The company also completes enrollment for its Phase 2/3 Study ‘306’, a 556-participant trial assessing the same treatment in female subjects.

Aug 2026Veradermics, Inc.News article

Veradermics presents subgroup analysis data from its Phase 2/3 Study ‘302’ evaluating a therapeutic for male pattern hair loss. The findings are shared at the 2026 American Academy of Dermatology Innovation Academy. The company specializes in late-stage biopharmaceutical solutions for hair loss treatments.

Jul 2026Veradermics, Inc.News article

Veradermics reports its oral VDPHL01 formulation shows early efficacy in treating female pattern hair loss. In Phase 2 trial **207**, most participants saw hair coverage improvements by Month 2, with sustained effects in ~89% of users (once-daily dosing). The results precede the upcoming Phase 2/3 study **306** readout.

Jul 2026Veradermics, Inc.News article